| 1. |
- Fodor, Gábor, et al.
(författare)
-
Device-to-device communications for national security and public safety
- 2014
-
Ingår i: IEEE Access. - 2169-3536. ; 2, s. 1510-1520
-
Tidskriftsartikel (refereegranskat)abstract
- Device-to-device (D2D) communications have been proposed as an underlay to long-term evolution (LTE) networks as a means of harvesting the proximity, reuse, and hop gains. However, D2D communications can also serve as a technology component for providing public protection and disaster relief (PPDR) and national security and public safety (NSPS) services. In the United States, for example, spectrum has been reserved in the 700-MHz band for an LTE-based public safety network. The key requirement for the evolving broadband PPDR and NSPS services capable systems is to provide access to cellular services when the infrastructure is available and to efficiently support local services even if a subset or all of the network nodes become dysfunctional due to public disaster or emergency situations. This paper reviews some of the key requirements, technology challenges, and solution approaches that must be in place in order to enable LTE networks and, in particular, D2D communications, to meet PPDR and NSPS-related requirements. In particular, we propose a clustering-procedure-based approach to the design of a system that integrates cellular and ad hoc operation modes depending on the availability of infrastructure nodes. System simulations demonstrate the viability of the proposed design. The proposed scheme is currently considered as a technology component of the evolving 5G concept developed by the European 5G research project METIS.
|
|
| 2. |
- Hindi, N., et al.
(författare)
-
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma : results from a retrospective worldwide registry
- 2023
-
Ingår i: ESMO Open. - 2059-7029. ; 8:6
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Conventional cytotoxic drugs are not effective in alveolar soft-part sarcoma (ASPS). Immune checkpoint (programmed cell death protein 1/programmed death-ligand 1) inhibitors (ICIs) are promising drugs in ASPS. A worldwide registry explored the efficacy of ICI in ASPS. Materials and methods: Data from adult patients diagnosed with ASPS and treated with ICI for advanced disease in expert sarcoma centers from Europe, Australia and North America were retrospectively collected, including demographics and data related to treatments and outcome. Results: Seventy-six ASPS patients, with a median age at diagnosis of 25 years (range 3-61 years), were registered. All patients received ICI for metastatic disease. Immunotherapy regimens consisted of monotherapy in 38 patients (50%) and combination in 38 (50%) (23 with a tyrosine kinase inhibitor). Among the 68 assessable patients, there were 3 complete responses and 34 partial responses, translating into an overall response rate of 54.4%. After a median follow-up of 36 months [95% confidence interval (CI) 32-40 months] since the start of immunotherapy, 45 (59%) patients have progressed on ICI, with a median progression-free survival (PFS) of 16.3 months (95% CI 8-25 months). Receiving ICI in first line (P = 0.042) and achieving an objective response (P = 0.043) correlated with a better PFS. Median estimated overall survival (OS) from ICI initiation has not been reached. The 12-month and 24-month OS rates were 94% and 81%, respectively. Conclusions: This registry constitutes the largest available series of ASPS treated with ICI. Our results suggest that the ICI treatment provides long-lasting disease control and prolonged OS in patients with advanced ASPS, an ultra-rare entity with limited active therapeutic options.
|
|
| 3. |
|
|
